• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

塌缩机制模型:在选择性不可逆拮抗剂概念验证剂量选择中的应用

Collapsing mechanistic models: an application to dose selection for proof of concept of a selective irreversible antagonist.

作者信息

Hutmacher Matthew M, Mukherjee Debu, Kowalski Kenneth G, Jordan David C

机构信息

Pfizer Corporation Pharmacometrics, 2800 Plymouth Road, Ann Arbor, MI 48015, USA.

出版信息

J Pharmacokinet Pharmacodyn. 2005 Aug;32(3-4):501-20. doi: 10.1007/s10928-005-0052-0.

DOI:10.1007/s10928-005-0052-0
PMID:16320102
Abstract

When data fail to support fully mechanistic models, alternative modeling strategies must be pursued. Simpler, more empirical models or the fixing of various rate constants are necessary to avoid over-parameterization. Fitting empirical models can dilute information, limit interpretation, and cloud inference. Fixing rate constants requires external, relevant, and reliable information on the mechanism and can introduce subjectivity as well as complicate determining the validity of model extrapolation. Furthermore, both these methods ignore the possibility that failure of the data to support the mechanistic model could contain information about the pharmacodynamic process. If the pathway has processes with "fast" dynamics, these steps could collapse yielding parametrically simpler classes of models. The collapsed models would retain the mechanistic interpretation of the full model, which is crucial for performing substantive inference, while reducing the number of parameters to be estimated. These concepts are illustrated through their manifestations on the dose-effect relationship and ensuing dose selection for a proof of concept study. Specifically, a mechanistic model for a selective irreversible antagonist was posited and candidate classes of models were derived utilizing "fast dynamics" assumptions. Model assessment determined the rate-limiting step facilitating pertinent inference with respect to the mechanism. For comparison, inference using a more empirical modeling strategy is also presented. A general solution for the collapse of the typical PK-PD model differential equations is provided in Appendix A.

摘要

当数据无法完全支持机理模型时,就必须采用其他建模策略。需要使用更简单、更具经验性的模型或固定各种速率常数,以避免过度参数化。拟合经验模型可能会稀释信息、限制解释并模糊推断。固定速率常数需要有关该机制的外部、相关且可靠的信息,并且可能会引入主观性,同时使确定模型外推有效性的过程变得复杂。此外,这两种方法都忽略了数据无法支持机理模型可能包含有关药效学过程信息的可能性。如果该途径具有“快速”动力学过程,这些步骤可能会合并,从而产生参数更简单的模型类别。合并后的模型将保留完整模型的机理解释,这对于进行实质性推断至关重要,同时减少了待估计的参数数量。通过它们在剂量 - 效应关系上的表现以及随后用于概念验证研究的剂量选择来说明这些概念。具体而言,提出了一种选择性不可逆拮抗剂的机理模型,并利用“快速动力学”假设推导出候选模型类别。模型评估确定了限速步骤,有助于对该机制进行相关推断。为作比较,还展示了使用更具经验性建模策略的推断。附录A中提供了典型PK - PD模型微分方程合并的一般解决方案。

相似文献

1
Collapsing mechanistic models: an application to dose selection for proof of concept of a selective irreversible antagonist.塌缩机制模型:在选择性不可逆拮抗剂概念验证剂量选择中的应用
J Pharmacokinet Pharmacodyn. 2005 Aug;32(3-4):501-20. doi: 10.1007/s10928-005-0052-0.
2
Preclinical pharmacokinetic/pharmacodynamic/efficacy relationships for alisertib, an investigational small-molecule inhibitor of Aurora A kinase.alisertib 的临床前药代动力学/药效学/疗效关系研究,alisertib 是一种新型小分子 Aurora A 激酶抑制剂。
Cancer Chemother Pharmacol. 2013 Dec;72(6):1255-64. doi: 10.1007/s00280-013-2305-8. Epub 2013 Oct 8.
3
A pharmacokinetic-pharmacodynamic disease model to predict in vivo antiviral activity of maraviroc.一种用于预测马拉维若体内抗病毒活性的药代动力学-药效学疾病模型。
Clin Pharmacol Ther. 2005 Nov;78(5):508-19. doi: 10.1016/j.clpt.2005.07.010. Epub 2005 Sep 28.
4
Comparison of different pharmacodynamic models for PK-PD modeling of verapamil in renovascular hypertension.维拉帕米在肾血管性高血压中进行药代动力学-药效学建模的不同药效学模型比较
J Pharmacol Toxicol Methods. 2008 May-Jun;57(3):212-9. doi: 10.1016/j.vascn.2008.03.002. Epub 2008 Mar 19.
5
Characterizing the PK/PD relationship for inhibition of capsaicin-induced dermal vasodilatation by MK-3207, an oral calcitonin gene related peptide receptor antagonist.表征口服降钙素基因相关肽受体拮抗剂MK-3207抑制辣椒素诱导的皮肤血管舒张的药代动力学/药效学关系。
Br J Clin Pharmacol. 2015 May;79(5):831-7. doi: 10.1111/bcp.12547.
6
Use of in vitro data in developing a physiologically based pharmacokinetic model: Carbaryl as a case study.利用体外数据构建基于生理学的药代动力学模型:以西维因为例进行研究。
Toxicology. 2015 Jun 5;332:52-66. doi: 10.1016/j.tox.2014.05.006. Epub 2014 May 24.
7
Basic concepts of pharmacokinetic/pharmacodynamic (PK/PD) modelling.药代动力学/药效学(PK/PD)建模的基本概念。
Int J Clin Pharmacol Ther. 1997 Oct;35(10):401-13.
8
Pharmacokinetics and concentration-effect analysis of intravenous RGD891, a platelet GPIIb/IIIa antagonist, using mixed-effects modeling (NONMEM).使用混合效应模型(NONMEM)对血小板糖蛋白IIb/IIIa拮抗剂静脉注射RGD891进行药代动力学和浓度-效应分析。
J Clin Pharmacol. 2000 Oct;40(10):1129-40.
9
Nociceptive stimulus modality-related difference in pharmacokinetic-pharmacodynamic modeling of morphine in the rat.大鼠中吗啡药代动力学-药效学模型中伤害性刺激模式相关的差异。
Pharmacol Biochem Behav. 2006 Oct;85(2):464-73. doi: 10.1016/j.pbb.2006.09.016. Epub 2006 Nov 27.
10
The minimum anticipated biological effect level (MABEL) for selection of first human dose in clinical trials with monoclonal antibodies.临床试验中选择单克隆抗体首次人体剂量的最低预期生物学效应水平(MABEL)。
Curr Opin Biotechnol. 2009 Dec;20(6):722-9. doi: 10.1016/j.copbio.2009.10.013. Epub 2009 Nov 5.

引用本文的文献

1
Modelling the delay between pharmacokinetics and EEG effects of morphine in rats: binding kinetic versus effect compartment models.建立吗啡在大鼠体内药代动力学和脑电图效应之间的时滞模型:结合动力学模型与效应室模型。
J Pharmacokinet Pharmacodyn. 2018 Aug;45(4):621-635. doi: 10.1007/s10928-018-9593-x. Epub 2018 May 18.
2
Improvement in latent variable indirect response joint modeling of a continuous and a categorical clinical endpoint in rheumatoid arthritis.类风湿关节炎中连续和分类临床终点的潜在变量间接反应联合建模的改进
J Pharmacokinet Pharmacodyn. 2016 Feb;43(1):45-54. doi: 10.1007/s10928-015-9453-x. Epub 2015 Nov 9.
3

本文引用的文献

1
Use of prior information to stabilize a population data analysis.利用先验信息稳定总体数据分析。
J Pharmacokinet Pharmacodyn. 2002 Dec;29(5-6):473-505. doi: 10.1023/a:1022972420004.
2
Evaluating pharmacokinetic/pharmacodynamic models using the posterior predictive check.使用后验预测检验评估药代动力学/药效学模型。
J Pharmacokinet Pharmacodyn. 2001 Apr;28(2):171-92. doi: 10.1023/a:1011555016423.
3
Time-dependent oral absorption models.时间依赖性口服吸收模型。
Exposure-response modeling of clinical end points using latent variable indirect response models.
使用潜在变量间接响应模型对临床终点进行暴露-反应建模。
CPT Pharmacometrics Syst Pharmacol. 2014 Jun 4;3(6):e117. doi: 10.1038/psp.2014.15.
4
Mechanism-based pharmacokinetic/pharmacodynamic modeling of rat prefrontal cortical dopamine response to dual acting norepinephrine reuptake inhibitor and 5-HT1A partial agonist.基于机制的大鼠前额皮质多巴胺对双重作用去甲肾上腺素再摄取抑制剂和 5-HT1A 部分激动剂反应的药代动力学/药效学模型。
AAPS J. 2012 Jun;14(2):365-76. doi: 10.1208/s12248-012-9343-8. Epub 2012 Mar 28.
5
Fractional dynamics pharmacokinetics-pharmacodynamic models.分数阶动力学药代动力学-药效动力学模型。
J Pharmacokinet Pharmacodyn. 2010 Jun;37(3):257-76. doi: 10.1007/s10928-010-9159-z. Epub 2010 May 9.
6
Exposure-response modeling using latent variables for the efficacy of a JAK3 inhibitor administered to rheumatoid arthritis patients.使用潜在变量进行暴露-反应建模,以评估给予类风湿关节炎患者的一种JAK3抑制剂的疗效。
J Pharmacokinet Pharmacodyn. 2008 Apr;35(2):139-57. doi: 10.1007/s10928-007-9080-2. Epub 2007 Dec 6.
J Pharmacokinet Pharmacodyn. 2001 Apr;28(2):109-28. doi: 10.1023/a:1011573831444.
4
A model for the turnover of dihydrotestosterone in the presence of the irreversible 5 alpha-reductase inhibitors GI198745 and finasteride.在不可逆5α-还原酶抑制剂GI198745和非那雄胺存在的情况下二氢睾酮周转的模型。
Clin Pharmacol Ther. 1998 Dec;64(6):636-47. doi: 10.1016/S0009-9236(98)90054-6.
5
Characterization of four basic models of indirect pharmacodynamic responses.四种间接药效学反应基本模型的表征
J Pharmacokinet Biopharm. 1996 Dec;24(6):611-35. doi: 10.1007/BF02353483.
6
Convergence of direct and indirect pharmacodynamic response models.直接和间接药效学反应模型的融合。
J Pharmacokinet Biopharm. 1995 Feb;23(1):5-8; discussion 9-10. doi: 10.1007/BF02353781.
7
A general conceptual model for non-steady state pharmacokinetic/pharmacodynamic data.
J Pharmacokinet Biopharm. 1995 Feb;23(1):1-4. doi: 10.1007/BF02353780.
8
Comparison of four basic models of indirect pharmacodynamic responses.四种间接药效学反应基本模型的比较。
J Pharmacokinet Biopharm. 1993 Aug;21(4):457-78. doi: 10.1007/BF01061691.